person · Reporting owner
Murphy Christopher M.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Chief Financial Officer | May 11, 2026 | May 13, 2026 |
| Third Harmonic Bio, Inc.THRD · Entity 76517 | Chief Financial & Bus. Officer | August 11, 2025 | August 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date May 11, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,765 |
Reported balance
After 2026-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-11 · Grant · Acquired 25,765 · Balance 25,765 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2: The RSUs vests as to 25% of the total RSUs annually commencing on May 11, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2: The RSUs vests as to 25% of the total RSUs annually commencing on May 11, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Third Harmonic Bio, Inc.
Report date August 11, 2025 · Filed August 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-08-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-08-11 · Other · Disposed 47,500 · Balance 0 F1: The restricted stock units were deemed vested and settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share. F2: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units were deemed vested and settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share.
F2: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2026 Filed May 13, 2026 21:48 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Units · Derivative | 25,765 | $0.00 | $0.00 |
DisclosureSEC source: 0002005986-26-000002 · form4-05132026_090546.xml · derivative · entry 1 Murphy Christopher M. · CIK 0002005986 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,765 Underlying: Common Stock · 25,765 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on May 11, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on May 11, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 20:07 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | OtherRestricted Stock Unit · Derivative | 47,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-021823 · form4-08142025_080831.xml · derivative · entry 1 Murphy Christopher M. · CIK 0002005986 · Chief Financial & Bus. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,500 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units were deemed vested and settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share. F2 · kind: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer. F1 · derivative.exercise_date: The restricted stock units were deemed vested and settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share. F1 · derivative.expiration_date: The restricted stock units were deemed vested and settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 21:01 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006916 · form4-03052025_090325.xml · derivative · entry 1 Murphy Christopher M. · CIK 0002005986 · Chief Financial & Bus. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSU vests 100% on the one year anniversary of the grant date, subject to continued service through each vesting date. F2 · derivative.expiration_date: The RSU vests 100% on the one year anniversary of the grant date, subject to continued service through each vesting date. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 23:10 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantRestricted Stock Unit · Derivative | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001725 · form4-01172025_110130.xml · derivative · entry 2 Murphy Christopher M. · CIK 0002005986 · Chief Financial & Bus. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F1 · kind: The equity awards of the Reporting Person in this Form 4 were approved on December 17, 2024 by the board of directors as part of the annual refresh equity grant process of the registrant with an effective grant date of January 15, 2025. F4 · derivative.exercise_date: The RSU vests over a four-year period: 1/4 on Febuary 15, 2026, after which 1/4 of the total shares vest annually, subject to contioued service through each vestiog date. F4 · derivative.expiration_date: The RSU vests over a four-year period: 1/4 on Febuary 15, 2026, after which 1/4 of the total shares vest annually, subject to contioued service through each vestiog date. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 23:10 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001725 · form4-01172025_110130.xml · derivative · entry 1 Murphy Christopher M. · CIK 0002005986 · Chief Financial & Bus. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2035-01-14 F1 · kind: The equity awards of the Reporting Person in this Form 4 were approved on December 17, 2024 by the board of directors as part of the annual refresh equity grant process of the registrant with an effective grant date of January 15, 2025. F2 · derivative.exercise_date: The option vests over a four-year period: 2.0833% shall vest on February 15, 2025, after which 2.0833% of the total shares vest monthly, subject to contioued service through each vestiog date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:05 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Option Grant (right to buy) · Derivative | 410,000 | $0.00 Strike: $10.89 | $0.00 |
DisclosureSEC source: 0001209191-24-001230 · doc4.xml · derivative · entry 1 Murphy Christopher M. · CIK 0002005986 · Chief Financial & Bus. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2034-01-04 F1 · derivative.exercise_date: 25% of the total shares vest on January 5, 2025, and thereafter 2.0833% of the total shares underlying the award shall vest in equal monthly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.